Wolfe Research Upgrades Immunovant to Outperform with $50 Target
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
NOTRELOAD AI
Arrowhead Gene Drug Doubles Weight Loss in Obesity Trial
Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
FDA Grants Breakthrough Status to Alkermes New Narcolepsy Drug
FDA grants Breakthrough Therapy status to alixorexton for narcolepsy type 1. Clinical trials show promising results for daytime wakefulness.
BMB-101 Drug Trial Shows 73% Seizure Reduction in Patients
Bright Minds Biosciences (DRUG) reports positive Phase 2 trial results for BMB-101, showing significant seizure reduction in patients with drug-resistant epilepsy.
Alumis Psoriasis Drug Achieves 90% Skin Clearance in Phase 3 Trials
Alumis (ALMS) announces breakthrough Phase 3 results for envudeucitinib, a new oral medication for moderate-to-severe plaque psoriasis showing exceptional skin clearance rates.
Instil Bio Ends Development of Cancer Drug AXN-2510
Instil Bio's subsidiary Axion Bio discontinues clinical development of AXN-2510 and terminates collaboration agreement with ImmuneOnco, returning rights to the Chinese partner.